Kura Oncology Overview
- Founded
- 2014

- Status
- Public
- Employees
- 83

- Stock Symbol
- KURA

- Investments
- 1
- Share Price
- $29.73
- (As of Wednesday Closing)
Kura Oncology General Information
Description
Kura Oncology Inc is a clinical-stage biopharmaceutical company, engages in discovering and developing therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small-molecule product candidates that target cell signalling pathways to drive the progression of various cancers. The company has lead product candidate, Tipifarnib, which is a farnesyl transferase inhibitor, in both solid tumors and blood cancers. It is advancing KO-947, a small molecule inhibitor of extracellular-signal-regulated kinase (ERK), as a treatment for patients with pancreatic cancer, colorectal cancer, non-small cell lung cancer (NSCLC) and melanoma. Geographically operation of the group is carried through the United States.
Contact Information
- 12730 High Bluff Drive
- Suite 400
- San Diego, CA 92130
- United States
Kura Oncology Stock Performance
(As of Wednesday Closing)
Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
---|---|---|---|---|---|---|
$29.73 | $32.80 | $6.35 - $43.00 | $1.96B | 66M | 867K | -$1.63 |
Kura Oncology Financials Summary
In Thousands, USD |
TTM 30-Sep-2020 | FY 2019 31-Dec-2019 | FY 2018 31-Dec-2018 | FY 2017 31-Dec-2017 |
---|---|---|---|---|
EV | 1,400,909 | 380,451 | 352,882 | 368,535 |
Revenue | 0 | 0 | 0 | 0 |
EBITDA | (84,391) | (67,234) | (62,636) | (35,267) |
Net Income | (81,331) | (63,140) | (60,447) | (35,434) |
Total Assets | 339,567 | 241,972 | 182,379 | 95,851 |
Total Debt | 15,426 | 7,500 | 7,500 | 7,098 |
Kura Oncology Valuation & Funding
Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
---|
This information is available in the PitchBook Platform. To explore Kura Oncology‘s full profile, request access.
Request a free trialKura Oncology Executive Team (15)
Kura Oncology Board Members (7)
Name | Representing | Role | Since |
---|---|---|---|
Diane Parks | Self | Board Member | 000 0000 |
Faheem Hasnain | Self | Board Member | 000 0000 |
Mary Szela | Self | Board Member | 000 0000 |
Robert Hoffman | Self | Board Member | 000 0000 |
Steven Stein MD | Self | Board Member | 000 0000 |
Kura Oncology Signals
Growth Rate

Growth

Size Multiple


Key Data Points
Twitter Followers
5.5k

Similarweb Unique Visitors
15.0K

Majestic Referring Domains
314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trialKura Oncology Acquisitions (1)
Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
---|---|---|---|---|---|
0000 00000000000 | 06-Mar-2015 | 000000000000000000 | Holding Companies |